Systemic Sclerosis-Associated Interstitial Lung Disease: Improved Understanding and Advances in Management

Area of Science:

• Rheumatology
• Pulmonology
• Medical Imaging
• Biomarkers

Background:

• Interstitial lung disease (ILD) is a severe complication of systemic sclerosis (SSc), leading to significant morbidity and mortality, especially in diffuse cutaneous SSc (dcSSc).
• Early detection and monitoring of SSc-ILD are crucial for effective management.
• Recent therapeutic advancements have expanded treatment options for SSc-ILD.

Purpose of the Study:

• To synthesize current screening, monitoring, and therapeutic strategies for SSc-ILD.
• To highlight recent advancements in AI-based diagnostics, serological biomarkers, and updated international treatment guidelines.
• To discuss emerging combination and triple therapy approaches and propose future research directions.

Main Methods:

• Review of recent literature on SSc-ILD diagnostics and therapeutics.
• Analysis of advancements in artificial intelligence (AI)-enhanced high-resolution computed tomography (HRCT).
• Evaluation of serological biomarkers, including Krebs von den Lungen (KL)-6.
• Synthesis of updated international guidelines (ACR, CHEST, ATS, EULAR).

Main Results:

• AI-enhanced HRCT and biomarkers like KL-6 facilitate earlier SSc-ILD detection and monitoring.
• Antifibrotics (e.g., nintedanib) and immunomodulators (e.g., tocilizumab) are now established therapeutic options.
• Updated guidelines reflect the evolving treatment landscape, including combination therapies.

Conclusions:

• The management of SSc-ILD is shifting towards proactive screening, precise monitoring using novel diagnostics, and personalized therapeutic strategies.
• Combination and potentially triple therapy approaches represent a significant advancement in treating SSc-ILD.
• Future research should focus on biomarker validation, mechanistic insights, and optimizing personalized treatment plans for SSc-ILD.